ESHG Webinar Series Season 2 Episode 3 with Lili Milani

Value of the Information & Strength of the Argument

The webinar provides valuable insights into the application of long-read sequencing for pharmacogenomics, showcasing concrete examples of novel variants and their potential clinical impact. The argumentation is solid, based on data from the Estonian Biobank and published studies. The speaker effectively demonstrates the limitations of short-read sequencing and the importance of phasing for accurate interpretation. The recall study adds experimental validation, strengthening the evidence. However, some results are preliminary and not yet peer-reviewed, and the webinar format limits the depth of methodological detail.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with references to published studies and ongoing projects. The speaker cites specific collaborations and datasets, but specific citations are not provided in the talk. The title accurately reflects the content. The webinar is based on original research and expert knowledge, but as a presentation, it does not include formal citations. The description mentions a recent paper on the biobank, but no direct links are given.

The title accurately reflects the content, which focuses on pharmacogenomic studies in the Estonian Biobank.

8/10

The webinar presents original research from the Estonian Biobank, including long-read sequencing data and pharmacogenomic studies. The speaker is a leading expert, and the content is based on published and ongoing research. However, as a webinar, it lacks peer review and detailed methodology, and some results are preliminary.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction by host, Inga, and presentation of Lili Milani.
• 02:00Overview of the Estonian Biobank: 20% of adult population, genotyped, metabolomics, EHR updates, questionnaires.
• 05:00Discussion of 'valleys of death' and return of results pilot studies.
• 10:00Introduction of the Teaming for Personalized Medicine project and 10,000 long-read genomes.
• 15:00Comparison of short-read vs long-read sequencing for CYP2D6 detection.
• 20:00Results from first 4,400 genomes: 72 CYP2D6 alleles, hybrid genes, and novel variants.
• 25:00Detection of DPYD exon 4 deletion and other rare variants.
• 30:00Methods to extract pharmacogenomic phenotypes from EHRs: adverse events, drug purchases, questionnaires.
• 35:00GWAS of penicillin allergy and text mining of free-text records.
• 40:00Machine learning for adverse drug reaction extraction and validation with CYP2C19.
• 45:00Real-world drug dosing data and genetic associations (statins, metoprolol, warfarin).
• 50:00Recall study for novel CYP2C19 and CYP2D6 variants with pharmacokinetic phenotyping.
• 55:00MyGenome portal for returning results and future directions.

• Estonian Biobank research paper (mentioned but not specified) — Referenced as a recent paper describing the biobank.

• PharmGKB — Database for pharmacogenomic knowledge, consistent with the webinar's focus on pharmacogenes.